184 related articles for article (PubMed ID: 32211615)
1. Importance of Endotoxin Clearance in Endotoxemic Septic Shock: An Analysis From the Evaluating Use of PolymyxinB Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemic Septic Shock (EUPHRATES) Trial.
Rachoin JS; Foster D; Giese R; Weisberg LS; Klein DJ
Crit Care Explor; 2020 Feb; 2(2):e0083. PubMed ID: 32211615
[TBL] [Abstract][Full Text] [Related]
2. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial.
Klein DJ; Foster D; Walker PM; Bagshaw SM; Mekonnen H; Antonelli M
Intensive Care Med; 2018 Dec; 44(12):2205-2212. PubMed ID: 30470853
[TBL] [Abstract][Full Text] [Related]
3. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.
Dellinger RP; Bagshaw SM; Antonelli M; Foster DM; Klein DJ; Marshall JC; Palevsky PM; Weisberg LS; Schorr CA; Trzeciak S; Walker PM;
JAMA; 2018 Oct; 320(14):1455-1463. PubMed ID: 30304428
[TBL] [Abstract][Full Text] [Related]
4. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial.
Klein DJ; Foster D; Schorr CA; Kazempour K; Walker PM; Dellinger RP
Trials; 2014 Jun; 15():218. PubMed ID: 24916483
[TBL] [Abstract][Full Text] [Related]
5. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial.
Iba T; Fowler L
J Intensive Care; 2017; 5():40. PubMed ID: 28690852
[TBL] [Abstract][Full Text] [Related]
6. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.
Cruz DN; Antonelli M; Fumagalli R; Foltran F; Brienza N; Donati A; Malcangi V; Petrini F; Volta G; Bobbio Pallavicini FM; Rottoli F; Giunta F; Ronco C
JAMA; 2009 Jun; 301(23):2445-52. PubMed ID: 19531784
[TBL] [Abstract][Full Text] [Related]
7. Up-to-date information on polymyxin B-immobilized fiber column direct hemoperfusion for septic shock.
Mitaka C; Kusaoi M; Kawagoe I; Satoh D
Acute Crit Care; 2021 May; 36(2):85-91. PubMed ID: 33813808
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial.
Osawa I; Goto T; Kudo D; Hayakawa M; Yamakawa K; Kushimoto S; Foster DM; Kellum JA; Doi K
Crit Care; 2023 Jun; 27(1):245. PubMed ID: 37344804
[TBL] [Abstract][Full Text] [Related]
9. Impact of polymyxin B hemoperfusion in the treatment of patients with sepsis and septic shock: a meta-analysis of randomized controlled trials.
Kuriyama A; Katsura M; Urushidani S; Takada T
Ann Transl Med; 2018 Jun; 6(11):206. PubMed ID: 30023369
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock.
Shoji H; Opal SM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672437
[TBL] [Abstract][Full Text] [Related]
11. PMX endotoxin removal in the clinical practice: results from the EUPHAS trial.
Antonelli M; Fumagalli R; Cruz DN; Brienza N; Giunta F
Contrib Nephrol; 2010; 167():83-90. PubMed ID: 20519902
[TBL] [Abstract][Full Text] [Related]
12. Polymyxin B hemoperfusion: a mechanistic perspective.
Ronco C; Klein DJ
Crit Care; 2014 Jun; 18(3):309. PubMed ID: 25043934
[TBL] [Abstract][Full Text] [Related]
13. Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action.
Shoji H; Ferrer R
J Anesth Analg Crit Care; 2022 Jun; 2(1):27. PubMed ID: 37386673
[TBL] [Abstract][Full Text] [Related]
14. Clinical Effects and Outcomes After Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion Treatment for Septic Shock in Preterm Neonates.
Nishizaki N; Hara T; Obinata K; Nakagawa M; Shimizu T
Pediatr Crit Care Med; 2020 Feb; 21(2):156-163. PubMed ID: 31568052
[TBL] [Abstract][Full Text] [Related]
15. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis.
Iwagami M; Yasunaga H; Doi K; Horiguchi H; Fushimi K; Matsubara T; Yahagi N; Noiri E
Crit Care Med; 2014 May; 42(5):1187-93. PubMed ID: 24365858
[TBL] [Abstract][Full Text] [Related]
16. Impact of hemoperfusion with polymyxin B added to hemofiltration in patients with endotoxic shock: a case-control study.
Navas A; Ferrer R; Martínez ML; Gomà G; Gili G; Masip J; Suárez D; Artigas A
Ann Intensive Care; 2018 Dec; 8(1):121. PubMed ID: 30535929
[TBL] [Abstract][Full Text] [Related]
17. Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES.
Rachoin JS; Foster D; Dellinger RP
Contrib Nephrol; 2010; 167():111-118. PubMed ID: 20519905
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock: A systematic review and meta-analysis.
Li X; Liu C; Mao Z; Qi S; Song R; Zhou F
J Crit Care; 2021 Jun; 63():187-195. PubMed ID: 33012579
[TBL] [Abstract][Full Text] [Related]
19. Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock.
Mitaka C; Tomita M
Shock; 2011 Oct; 36(4):332-8. PubMed ID: 21654557
[TBL] [Abstract][Full Text] [Related]
20. Endotoxin removal: bringing the mission to North America.
Foster D; Klein DJ; Guadagni G; Walker PM
Blood Purif; 2014; 37 Suppl 1():14-7. PubMed ID: 24457490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
